I'm replying to myself here, but....
Study 305:
This is OnCARlytics in combo with Blinatumomab, made by Amgen and marketed as "Blincyto."
At present, Blincyto is just a second line treatment for a particular and relatively uncommon type of leukaemia, but Blincyto is an FDA approved drug. I doubt it's a big seller, but Amgen is huge. Big Pharma.
And now they discover that their already approved niche product - Blincyto - when used in combination with OnCARlytics - shows "specific tumor cell killing in vitro and robust anti-tumor efficacy" against "in vivo human triple-negative breast cancer". ie. one of the hardest to treat types of cancer.
I think Amgen will be beyond interested in this result.
Cheers
Dave
Media Thread, page-7368
-
- There are more pages in this discussion • 8,367 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 4.9¢ | 4.8¢ | $328.5K | 6.792M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 5443565 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 2171910 | 5 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |